<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20960301</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-820X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Virologica Sinica</Title><ISOAbbreviation>Virol Sin</ISOAbbreviation></Journal><ArticleTitle>Strategies for antiviral screening targeting early steps of virus infection.</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>293</EndPage><MedlinePgn>281-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12250-010-3135-z</ELocationID><Abstract><AbstractText>Viral infection begins with the entry of the virus into the host target cell and initiates replication. For this reason, the virus entry machinery is an excellent target for antiviral therapeutics. In general, a virus life cycle includes several major steps: cell-surface attachment, entry, replication, assembly, and egress, while some viruses involve another stage called latency. The early steps of the virus life cycle include virus attachment, receptor binding, and entry. These steps involve the initial interactions between a virus and the host cell and thus are major determinants of the tropism of the virus infection, the nature of the virus replication, and the diseases resulting from the infection. Owing to the pathological importance of these early steps in the progress of viral infectious diseases, the development of inhibitors against these steps has been the focus of the pharmaceutical industry. In this review, Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), and Human Enterovirus 71 (EV71) were used as representatives of enveloped DNA, enveloped RNA, and non-enveloped viruses, respectively. The current mechanistic understanding of their attachment and entry, and the strategies for antagonist screenings are summarized herein.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China. peng_tao@gibh.ac.cn</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virol Sin</MedlineTA><NlmUniqueID>101514185</NlmUniqueID><ISSNLinking>1995-820X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018139" MajorTopicYN="N">Simplexvirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="N">Virus Attachment</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20960301</ArticleId><ArticleId IdType="pmc">PMC8227918</ArticleId><ArticleId IdType="doi">10.1007/s12250-010-3135-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agnello V., Abel G., Elfahal M., et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA. 1999;96:12766&#x2013;12771. doi: 10.1073/pnas.96.22.12766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.22.12766</ArticleId><ArticleId IdType="pmc">PMC23090</ArticleId><ArticleId IdType="pubmed">10535997</ArticleId></ArticleIdList></Reference><Reference><Citation>Arduino P. G., Porter S. R. Herpes Simplex Virus Type 1 infection: overview on relevant clinicopathological features. J Oral Pathol Med. 2008;37:107&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">18197856</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasiu D., Whitbeck J. C., de Leon M.P., et al. Bimolecular complementation defines functional regions of HSV gB that are involved with gH/gL as necessary steps leading to cell fusion. J Virol. 2010;84:3825&#x2013;3834. doi: 10.1128/JVI.02687-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02687-09</ArticleId><ArticleId IdType="pmc">PMC2849501</ArticleId><ArticleId IdType="pubmed">20130048</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee M., Khayat R., Walukiewicz H. E., et al. Dissecting the functional domains of a nonenveloped virus membrane penetration peptide. J Virol. 2009;83:6929&#x2013;6933. doi: 10.1128/JVI.02299-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02299-08</ArticleId><ArticleId IdType="pmc">PMC2698515</ArticleId><ArticleId IdType="pubmed">19369344</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth H., Schafer C., Adah M. I., et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem. 2003;278:41003&#x2013;41012. doi: 10.1074/jbc.M302267200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M302267200</ArticleId><ArticleId IdType="pubmed">12867431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartosch B., Cosset F. L. Cell entry of hepatitis C virus. Virology. 2006;348:1&#x2013;12. doi: 10.1016/j.virol.2005.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.12.027</ArticleId><ArticleId IdType="pubmed">16455127</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu A., Kanda T., Beyene A., et al. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol. 2007;81:3933&#x2013;3941. doi: 10.1128/JVI.02622-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02622-06</ArticleId><ArticleId IdType="pmc">PMC1866147</ArticleId><ArticleId IdType="pubmed">17287282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender F. C., Whitbeck J. C., Lou H., et al. Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J Virol. 2005;79:11588&#x2013;11597. doi: 10.1128/JVI.79.18.11588-11597.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.18.11588-11597.2005</ArticleId><ArticleId IdType="pmc">PMC1212636</ArticleId><ArticleId IdType="pubmed">16140736</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertaux C., Dragic T. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J Virol. 2006;80:4940&#x2013;4948. doi: 10.1128/JVI.80.10.4940-4948.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.80.10.4940-4948.2006</ArticleId><ArticleId IdType="pmc">PMC1472091</ArticleId><ArticleId IdType="pubmed">16641285</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevilacqua F., Marcello A., Toni M., et al. Acyclovir resistance/susceptibility in herpes simplex virus type 2 sequential isolates from an AIDS patient. J Acquir Immune Defic Syndr. 1991;4:967&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">1832460</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandenburg B., Lee L. Y., Lakadamyali M., et al. Imaging poliovirus entry in live cells. PLoS Biol. 2007;5:e183. doi: 10.1371/journal.pbio.0050183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0050183</ArticleId><ArticleId IdType="pmc">PMC1914398</ArticleId><ArticleId IdType="pubmed">17622193</ArticleId></ArticleIdList></Reference><Reference><Citation>Budkowska A. Mechanism of cell infection with hepatitis C virus (HCV)-a new paradigm in virus-cell interaction. Pol J Microbiol. 2009;58:93&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">19824391</ArticleId></ArticleIdList></Reference><Reference><Citation>Burlone M. E., Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol. 2009;90:1055&#x2013;1070. doi: 10.1099/vir.0.008300-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.008300-0</ArticleId><ArticleId IdType="pubmed">19264629</ArticleId></ArticleIdList></Reference><Reference><Citation>Campadelli-Fiume G., Amasio M., Avitabile E., et al. The multipartite system that mediates entry of herpes simplex virus into the cell. Rev Med Virol. 2007;17:313&#x2013;326. doi: 10.1002/rmv.546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.546</ArticleId><ArticleId IdType="pubmed">17573668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandran K., Farsetta D. L., Nibert M. L. Strategy for nonenveloped virus entry: a hydrophobic conformer of the reovirus membrane penetration protein micro 1 mediates membrane disruption. J Virol. 2002;76:9920&#x2013;9933. doi: 10.1128/JVI.76.19.9920-9933.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.19.9920-9933.2002</ArticleId><ArticleId IdType="pmc">PMC136509</ArticleId><ArticleId IdType="pubmed">12208969</ArticleId></ArticleIdList></Reference><Reference><Citation>Codran A., Royer C., Jaeck D., et al. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol. 2006;87:2583&#x2013;2593. doi: 10.1099/vir.0.81710-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.81710-0</ArticleId><ArticleId IdType="pubmed">16894197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole N. L., Grose C. Membrane fusion mediated by herpesvirus glycoproteins: the paradigm of varicella-zoster virus. Rev Med Virol. 2003;13:207&#x2013;222. doi: 10.1002/rmv.377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.377</ArticleId><ArticleId IdType="pubmed">12820183</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E. Antiviral drugs in current clinical use. J Clin Virol. 2004;30:115&#x2013;133. doi: 10.1016/j.jcv.2004.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2004.02.009</ArticleId><ArticleId IdType="pubmed">15125867</ArticleId></ArticleIdList></Reference><Reference><Citation>Dicker I. B., Blasecki J. W., Seetharam S. Herpes simplex type1:lacZ recombinant viruses. II. Microtiter plate-based colorimetric assays for the discovery of new antiherpes agents and the points at which such agents disrupt the viral replication cycle. Antiviral Res. 1995;28:213&#x2013;224. doi: 10.1016/0166-3542(95)00049-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(95)00049-R</ArticleId><ArticleId IdType="pubmed">8629814</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreux M., Dao Thi V. L., Fresquet J., et al. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog. 2009;5:e1000310. doi: 10.1371/journal.ppat.1000310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000310</ArticleId><ArticleId IdType="pmc">PMC2636890</ArticleId><ArticleId IdType="pubmed">19229312</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R., de Vries R. D., Osterhaus A. D., et al. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis. 2008;198:659&#x2013;663. doi: 10.1086/590668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/590668</ArticleId><ArticleId IdType="pubmed">18627246</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubuisson J., Helle F., Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol. 2008;10:821&#x2013;827. doi: 10.1111/j.1462-5822.2007.01107.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-5822.2007.01107.x</ArticleId><ArticleId IdType="pubmed">18081727</ArticleId></ArticleIdList></Reference><Reference><Citation>Falanga A., Cantisani M., Pedone C., et al. Membrane fusion and fission: enveloped viruses. Protein Pept Lett. 2009;16:751&#x2013;759. doi: 10.2174/092986609788681760.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986609788681760</ArticleId><ArticleId IdType="pubmed">19601904</ArticleId></ArticleIdList></Reference><Reference><Citation>Falconer M. M., Gilbert J. M., Roper A. M., et al. Rotavirus-induced fusion from without in tissue culture cells. J Virol. 1995;69:5582&#x2013;5591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189413</ArticleId><ArticleId IdType="pubmed">7637004</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z. H., Wang Q. C., Nie Q. H., et al. DC-SIGN: binding receptor for HCV? World J Gastroenterol. 2004;10:925&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4717105</ArticleId><ArticleId IdType="pubmed">15052667</ArticleId></ArticleIdList></Reference><Reference><Citation>Field H., McMillan A., Darby G. The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs. J Infect Dis. 1981;143:281&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">6260876</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner J. A. Herpes simplex virion entry into and intracellular transport within mammalian cells. Adv Drug Deliv Rev. 2003;55:1497&#x2013;1513. doi: 10.1016/j.addr.2003.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2003.07.006</ArticleId><ArticleId IdType="pubmed">14597143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghukasyan V., Hsu Y. Y., Kung S. H., et al. Application of fluorescence resonance energy transfer resolved by fluorescence lifetime imaging microscopy for the detection of enterovirus 71 infection in cells. J Biomed Opt. 2007;12:1&#x2013;8. doi: 10.1117/1.2718582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/1.2718582</ArticleId><ArticleId IdType="pubmed">17477731</ArticleId></ArticleIdList></Reference><Reference><Citation>Grondin B., DeLuca N. Herpes simplex virus type 1 ICP4 promotes transcription preinitiation complex formation by enhancing the binding of TFIID to DNA. J Virol. 2000;74:11504&#x2013;11510. doi: 10.1128/JVI.74.24.11504-11510.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.24.11504-11510.2000</ArticleId><ArticleId IdType="pmc">PMC112430</ArticleId><ArticleId IdType="pubmed">11090147</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo H. T. A potential role of the heparan sulfate in the hepatitis C virus attachment. Acta Virol. 2008;52:7&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">18459830</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q., Xu C., Wu C., et al. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res. 2009;145:63&#x2013;73. doi: 10.1016/j.virusres.2009.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2009.06.005</ArticleId><ArticleId IdType="pubmed">19540283</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannah B. P., Cairns T. M., Bender F. C., et al. Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops. J Virol. 2009;83:6825&#x2013;6836. doi: 10.1128/JVI.00301-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00301-09</ArticleId><ArticleId IdType="pmc">PMC2698560</ArticleId><ArticleId IdType="pubmed">19369321</ArticleId></ArticleIdList></Reference><Reference><Citation>Heldwein E. E., Krummenacher C. Entry of herpesviruses into mammalian cells. Cell Mol Life Sci. 2008;65:1653&#x2013;1668. doi: 10.1007/s00018-008-7570-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-008-7570-z</ArticleId><ArticleId IdType="pmc">PMC11131758</ArticleId><ArticleId IdType="pubmed">18351291</ArticleId></ArticleIdList></Reference><Reference><Citation>Helle F., Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci. 2008;65:100&#x2013;112. doi: 10.1007/s00018-007-7291-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-007-7291-8</ArticleId><ArticleId IdType="pmc">PMC11131702</ArticleId><ArticleId IdType="pubmed">17914604</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu M., Zhang J., Flint M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA. 2003;100:7271&#x2013;7276. doi: 10.1073/pnas.0832180100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0832180100</ArticleId><ArticleId IdType="pmc">PMC165865</ArticleId><ArticleId IdType="pubmed">12761383</ArticleId></ArticleIdList></Reference><Reference><Citation>Iro M., Witteveldt J., Angus A. G., et al. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res. 2009;83:148&#x2013;155. doi: 10.1016/j.antiviral.2009.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.04.007</ArticleId><ArticleId IdType="pubmed">19397930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalia M, Jameel S. 2009. Virus entry paradigms. Amino Acids, DOI: 10.1007/s00726-009-0363-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088018</ArticleId><ArticleId IdType="pubmed">19826903</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsoudakis G., Kaul A., Steinmann E., et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol. 2006;80:5308&#x2013;5320. doi: 10.1128/JVI.02460-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02460-05</ArticleId><ArticleId IdType="pmc">PMC1472176</ArticleId><ArticleId IdType="pubmed">16699011</ArticleId></ArticleIdList></Reference><Reference><Citation>Laquerre S., Argnani R., Anderson D. B., et al. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J Virol. 1998;72:6119&#x2013;6130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110418</ArticleId><ArticleId IdType="pubmed">9621076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl1):74&#x2013;81. doi: 10.1111/j.1478-3231.2008.01934.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2008.01934.x</ArticleId><ArticleId IdType="pubmed">19207969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavillette D., Bartosch B., Nourrisson D., et al. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem. 2006;281:3909&#x2013;3917. doi: 10.1074/jbc.M509747200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M509747200</ArticleId><ArticleId IdType="pubmed">16356932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. C., Shih Y. F., Hsu S. P., et al. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal Biochem. 2003;316:162&#x2013;170. doi: 10.1016/S0003-2697(03)00053-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-2697(03)00053-8</ArticleId><ArticleId IdType="pubmed">12711336</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. C., Yu M. C., Lien T. W., et al. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors. Assay Drug Dev Technol. 2005;3:385&#x2013;392. doi: 10.1089/adt.2005.3.385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/adt.2005.3.385</ArticleId><ArticleId IdType="pubmed">16180993</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung W. C. Cooperation between herpes simplex virus specific alpha protein and host cell RNA polymerase II in the transcription of viral deoxypyrimidine kinase. Can J Microbiol. 1980;26:401&#x2013;404. doi: 10.1139/m80-066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/m80-066</ArticleId><ArticleId IdType="pubmed">6250695</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y. X., Xie J. J., He Y. X., et al. Study of the clinical and laboratory features of hand-foot-mouth disease] Chinese J Exp Clin Virol. 2008;22:475&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">19544650</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozach P. Y., Amara A., Bartosch B., et al. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem. 2004;279:32035&#x2013;45. doi: 10.1074/jbc.M402296200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M402296200</ArticleId><ArticleId IdType="pubmed">15166245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig I. S., Lekkerkerker A. N., Depla E., et al. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J Virol. 2004;78:8322&#x2013;8332. doi: 10.1128/JVI.78.15.8322-8332.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.8322-8332.2004</ArticleId><ArticleId IdType="pmc">PMC446128</ArticleId><ArticleId IdType="pubmed">15254204</ArticleId></ArticleIdList></Reference><Reference><Citation>Madan R. P., Mesquita P. M., Cheshenko N., et al. Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol. 2007;81:7636&#x2013;7646. doi: 10.1128/JVI.02851-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02851-06</ArticleId><ArticleId IdType="pmc">PMC1933367</ArticleId><ArticleId IdType="pubmed">17494078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann A. M., Rusert P., Berlinger L., et al. HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS. 2009;23:1659&#x2013;1667. doi: 10.1097/QAD.0b013e32832e9408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e32832e9408</ArticleId><ArticleId IdType="pubmed">19581791</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfin F., Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol. 2003;26:29&#x2013;37. doi: 10.1016/S1386-6532(02)00263-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6532(02)00263-9</ArticleId><ArticleId IdType="pubmed">12589832</ArticleId></ArticleIdList></Reference><Reference><Citation>Morikawa K., Zhao Z., Date T., et al. The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. J Med Virol. 2007;79:714&#x2013;723. doi: 10.1002/jmv.20842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20842</ArticleId><ArticleId IdType="pubmed">17457918</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudhakir D., Harashima H. Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS J. 2009;11:65&#x2013;77. doi: 10.1208/s12248-009-9080-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-009-9080-9</ArticleId><ArticleId IdType="pmc">PMC2664881</ArticleId><ArticleId IdType="pubmed">19194803</ArticleId></ArticleIdList></Reference><Reference><Citation>Netski D. M., Mosbruger T., Depla E., et al. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis. 2005;41:667&#x2013;675. doi: 10.1086/432478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/432478</ArticleId><ArticleId IdType="pubmed">16080089</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Shimojima M., Tano Y., et al. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15:794&#x2013;797. doi: 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell C. D., Tiwari V., Oh M. J., et al. A role for heparan sulfate 3-O-sulfotransferase isoform 2 in herpes simplex virus type 1 entry and spread. Virology. 2006;346:452&#x2013;459. doi: 10.1016/j.virol.2005.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.11.003</ArticleId><ArticleId IdType="pubmed">16336986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortner B., Huang C. W., Schmid D., et al. Epidemiology of enterovirus types causing neurological disease in Austria 1999&#x2013;2007: detection of clusters of echovirus 30 and enterovirus 71 and analysis of prevalent genotypes. J Med Virol. 2009;81:317&#x2013;324. doi: 10.1002/jmv.21374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21374</ArticleId><ArticleId IdType="pubmed">19107980</ArticleId></ArticleIdList></Reference><Reference><Citation>Owsianka A. M., Timms J. M., Tarr A. W., et al. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol. 2006;80:8695&#x2013;704. doi: 10.1128/JVI.00271-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00271-06</ArticleId><ArticleId IdType="pmc">PMC1563869</ArticleId><ArticleId IdType="pubmed">16912317</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel K. P., Bergelson J. M. Receptors identified for hand, foot and mouth virus. Nat Med. 2009;15:728&#x2013;729. doi: 10.1038/nm0709-728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0709-728</ArticleId><ArticleId IdType="pubmed">19584857</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietschmann T., Kaul A., Koutsoudakis G., et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA. 2006;103:7408&#x2013;7413. doi: 10.1073/pnas.0504877103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0504877103</ArticleId><ArticleId IdType="pmc">PMC1455439</ArticleId><ArticleId IdType="pubmed">16651538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploss A., Evans M. J., Gaysinskaya V. A., et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature. 2009;457:882&#x2013;886. doi: 10.1038/nature07684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07684</ArticleId><ArticleId IdType="pmc">PMC2762424</ArticleId><ArticleId IdType="pubmed">19182773</ArticleId></ArticleIdList></Reference><Reference><Citation>Popescu C I, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell, 102:63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">19857204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajcani J., Vojvodova A. The role of herpes simplex virus glycoproteins in the virus replication cycle. Acta Virol. 1998;42:103&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">9770079</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S., Singh S., Poh C. L., et al. The hand, foot and mouth disease virus capsid: sequence analysis and prediction of antigenic sites from homology modelling. Appl Bioinformatics. 2002;1:43&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15130856</ArticleId></ArticleIdList></Reference><Reference><Citation>Reske A., Pollara G., Krummenacher C., et al. Understanding HSV-1 entry glycoproteins. Rev Med Virol. 2007;17:205&#x2013;215. doi: 10.1002/rmv.531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.531</ArticleId><ArticleId IdType="pmc">PMC7169067</ArticleId><ArticleId IdType="pubmed">17295428</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinazi R. F., Nahmias A. J. Different in vitro effects of dual combinations of anti-herpes simplex virus compounds. Am J Med. 1982;73:40&#x2013;48. doi: 10.1016/0002-9343(82)90061-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(82)90061-4</ArticleId><ArticleId IdType="pubmed">6285731</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz A. K., Grove J., Hu K., et al. Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J Virol. 2009;83:12407&#x2013;12414. doi: 10.1128/JVI.01552-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01552-09</ArticleId><ArticleId IdType="pmc">PMC2786758</ArticleId><ArticleId IdType="pubmed">19776133</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith J. S., Robinson N. J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 2002;186(Suppl1):S3&#x2013;28. doi: 10.1086/343739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/343739</ArticleId><ArticleId IdType="pubmed">12353183</ArticleId></ArticleIdList></Reference><Reference><Citation>Spear P.G. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol. 2004;6:401&#x2013;410. doi: 10.1111/j.1462-5822.2004.00389.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-5822.2004.00389.x</ArticleId><ArticleId IdType="pubmed">15056211</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranska R., Schuurman R., Scholl D. R., et al. ELVIRA HSV, a yield reduction assay for rapid herpes simplex virus susceptibility testing. Antimicrob Agents Chemother. 2004;48:2331&#x2013;2333. doi: 10.1128/AAC.48.6.2331-2333.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.6.2331-2333.2004</ArticleId><ArticleId IdType="pmc">PMC415590</ArticleId><ArticleId IdType="pubmed">15155247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M., Kodaira H., Nishiyama Y., et al. Construction of recombinant herpes simplex virus type I expressing green fluorescent protein without loss of any viral genes. Microbes Infect. 2004;6:485&#x2013;493. doi: 10.1016/j.micinf.2004.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2004.01.011</ArticleId><ArticleId IdType="pubmed">15109964</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani H., Komoda Y., Matsuo E., et al. Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol. 2007;81:8601&#x2013;8612. doi: 10.1128/JVI.00608-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00608-07</ArticleId><ArticleId IdType="pmc">PMC1951354</ArticleId><ArticleId IdType="pubmed">17553880</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor T. J., Knipe D. M. The use of green fluorescent fusion proteins to monitor herpes simplex virus replication. Methods Mol Biol. 2009;515:239&#x2013;248. doi: 10.1007/978-1-59745-559-6_16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-59745-559-6_16</ArticleId><ArticleId IdType="pubmed">19378129</ArticleId></ArticleIdList></Reference><Reference><Citation>Trybala E., Liljeqvist J. A., Svennerholm B., et al. Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate. J Virol. 2000;74:9106&#x2013;9114. doi: 10.1128/JVI.74.19.9106-9114.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.19.9106-9114.2000</ArticleId><ArticleId IdType="pmc">PMC102109</ArticleId><ArticleId IdType="pubmed">10982357</ArticleId></ArticleIdList></Reference><Reference><Citation>Tscherne D. M., Jones C. T., Evans M. J., et al. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol. 2006;80:1734&#x2013;1741. doi: 10.1128/JVI.80.4.1734-1741.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.80.4.1734-1741.2006</ArticleId><ArticleId IdType="pmc">PMC1367161</ArticleId><ArticleId IdType="pubmed">16439530</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q. C., Feng Z. H., Nie Q. H., et al. DC-SIGN: binding receptors for hepatitis C virus. Chin Med J (Engl) 2004;117:1395&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pubmed">15377434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M., Ho T. S., Shen C. F., et al. Enterovirus 71, one virus and many stories. Pediatr Neonatol. 2008;49:113&#x2013;115. doi: 10.1016/S1875-9572(08)60024-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1875-9572(08)60024-8</ArticleId><ArticleId IdType="pubmed">19054915</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. C., Kao C. L., Liu W. T., et al. A cell line that secretes inducibly a reporter protein for monitoring herpes simplex virus infection and drug susceptibility. J Med Virol. 2002;68:599&#x2013;605. doi: 10.1002/jmv.10230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.10230</ArticleId><ArticleId IdType="pubmed">12376969</ArticleId></ArticleIdList></Reference><Reference><Citation>Whidby J., Mateu G., Scarborough H., et al. Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. J Virol. 2009;83:11078&#x2013;11089. doi: 10.1128/JVI.00800-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00800-09</ArticleId><ArticleId IdType="pmc">PMC2772786</ArticleId><ArticleId IdType="pubmed">19710151</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright C. C., Wisner T. W., Hannah B. P., et al. Fusion between perinuclear virions and the outer nuclear membrane requires the fusogenic activity of herpes simplex virus gB. J Virol. 2009;83:11847&#x2013;11856. doi: 10.1128/JVI.01397-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01397-09</ArticleId><ArticleId IdType="pmc">PMC2772685</ArticleId><ArticleId IdType="pubmed">19759132</ArticleId></ArticleIdList></Reference><Reference><Citation>Wymer J. P., Chung T. D., Chang Y. N., et al. Identification of immediate-early-type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2. J Virol. 1989;63:2773&#x2013;2784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250777</ArticleId><ArticleId IdType="pubmed">2542589</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Yamashita Y., Li J., et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15:798&#x2013;801. doi: 10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Chuang H., Yang K. D. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J. 2009;6:141. doi: 10.1186/1743-422X-6-141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-6-141</ArticleId><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahn A., Allain J. P. Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J Gen Virol. 2005;86:677&#x2013;685. doi: 10.1099/vir.0.80614-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.80614-0</ArticleId><ArticleId IdType="pubmed">15722528</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel M. B., Barth H., Schuster C., et al. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci. 2009;14:3274&#x2013;3285. doi: 10.2741/3450.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/3450</ArticleId><ArticleId IdType="pmc">PMC3235086</ArticleId><ArticleId IdType="pubmed">19273272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel M. B., Baumert T. F. HCV entry and neutralizing antibodies: lessons from viral variants. Future Microbiol. 2009;4:511&#x2013;517. doi: 10.2217/fmb.09.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.09.34</ArticleId><ArticleId IdType="pmc">PMC2898794</ArticleId><ArticleId IdType="pubmed">19492962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler S., Kronenberger B., Albrecht B. A., et al. Development and evaluation of a FACS-based medium-throughput assay for HCV entry inhibitors. J Biomol Screen. 2009;14:620&#x2013;626. doi: 10.1177/1087057109337161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1087057109337161</ArticleId><ArticleId IdType="pubmed">19531666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>